Plus Therapeutics Announces Webinar to Present ReSPECT™ Glioblastoma Clinical Trial Update
November 13 2020 - 7:30AM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a
clinical-stage pharmaceutical company developing novel,
personalized and targeted therapies for rare and difficult to treat
cancers, today announced it will host a webinar on Thursday,
November 19, 2020, 4:30 to 5:30 p.m. ET. The call will follow a
poster presentation of new interim data from the ongoing National
Institutes of Health-sponsored ReSPECT™ Phase 1 clinical trial
evaluating the Company’s lead investigational asset, Rhenium
NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM)
at the 2020 Society for Neuro-Oncology (SNO) Annual Meeting.
The webinar will feature a discussion of the
interim safety, tolerability, dosing, feasibility and efficacy data
from the ongoing ReSPECT trial. Andrew J. Brenner, M.D., Ph.D.,
Associate Professor of Medicine, Neurology, and Neurosurgery at The
University of Texas, Health Services Center at San Antonio, will
provide an update on the ReSPECT trial and provide insight on the
trial data.
Marc Hedrick, M.D., President and Chief
Executive Officer of Plus Therapeutics, and Gregory D. Stein, M.D.,
M.B.A., Senior Vice President, Clinical Development of Plus
Therapeutics, will discuss the technology behind RNL as well as the
current treatment landscape and unmet medical need in treating
patients with recurrent GBM.
The sixth and final dose escalation cohort of
the ReSPECT trial is underway and is expected to fully enroll by
the end of 2020. In September 2020, the FDA granted both Orphan
Drug designation and Fast Track designation to RNL for the
treatment of patients with recurrent glioblastoma. Additional
details about the ReSPECT trial are available at clinicaltrials.gov
(NCT01906385).
Webcast Details
A live webinar with accompanying slides will be
available in the Events page of the ‘Investors’ section of the Plus
Therapeutics website or by clicking here. Individuals can
participate in an interactive Q&A session by submitting
pertinent questions via the webcast platform.
Please log in approximately 10 minutes prior to
the scheduled start time. The archived webcast will be available in
the Events section of the Company's website for 90 days.
A live audio conference will be available by
dialing (833) 340-0285 (toll-free) or (236) 712-2475 and entering
Conference ID 6095968.
Andrew J. Brenner, M.D.,
Ph.D.
Dr. Brenner is a nationally known expert in the
treatment of brain and breast cancers, with a particular research
interest in developing new treatments. He has served on multiple
committees and panels including for the National Institutes of
Health, National Cancer Institute, Department of Defense Breast
Cancer Research Program, and others. He has also served on advisory
committees for a number of companies to help direct development of
new drugs. His laboratory work developing new treatments has been
funded by the Food and Drug Administration, National Cancer
Institute, and Cancer Prevention and Research Institute of Texas.
He has published nearly 50 original research articles in peer
reviewed journals. Dr. Brenner is a member of the Plus Therapeutics
Scientific Advisory Board.
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a
clinical-stage pharmaceutical company whose radiotherapeutic
portfolio is concentrated on nanoliposome-encapsulated
radionuclides for several cancer targets. Central to the Company’s
drug development is a unique nanotechnology platform designed to
reformulate, deliver and commercialize multiple drugs targeting
rare cancers and other diseases. The platform is designed to
facilitate new delivery approaches and/or formulations of safe and
effective, injectable drugs, potentially enhancing the safety,
efficacy and convenience for patients and healthcare providers.
More information may be found at PlusTherapeutics.com and
ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains certain statements
that may be deemed “forward-looking statements” within the meaning
of U.S. securities laws. All statements, other than statements of
historical fact, that address activities, events or developments
that we intend, expect, project, believe or anticipate and similar
expressions or future conditional verbs such as will, should,
would, could or may occur in the future are forward-looking
statements. Such statements are based upon certain assumptions and
assessments made by our management in light of their experience and
their perception of historical trends, current conditions, expected
future developments and other factors they believe to be
appropriate. These statements include, without limitation,
statements about: the Company’s potential to facilitate new
delivery approaches and/or formulations of safe and effective,
injectable drugs, potentially enhancing the safety, efficacy and
convenience for patients and healthcare providers; the Company’s
potential to develop drug candidates currently in its product
pipeline; and the Company’s potential to develop additional drugs
outside of its current pipeline. The forward-looking statements
included in this press release are subject to a number of
additional material risks and uncertainties, including but not
limited to: the risk that the Company is not able to successfully
develop product candidates that can leverage the U.S. FDA’s
accelerated regulatory pathways; and the risks described under the
heading “Risk Factors” in the Company’s Securities and Exchange
Commission filings, including in the Company’s annual and quarterly
reports. There may be events in the future that the Company is
unable to predict, or over which it has no control, and its
business, financial condition, results of operations and prospects
may change in the future. The Company assumes no responsibility to
update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made unless the
Company has an obligation under U.S. federal securities laws to do
so.
Investor ContactPeter Vozzo Westwicke/ICR(443) 377-4767
Peter.Vozzo@westwicke.com
Media ContactTerri ClevengerWestwicke/ICR(203)
856-4326Terri.Clevenger@westwicke.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Apr 2023 to Apr 2024